06 Apr 2022
Current cancer therapies are difficult, expensive and slow to develop. But the combination of new computers and new biological technologies leads to a better understanding of the human immune system, with the aim of offering a better class of cancer therapies.
Azeem Azhar speaks with Luis Voloch, co-founder and chief technology officer of Immunai, about how AI is unlocking the secrets of the immune system and opening new avenues for new cancer treatments.
They also discuss:
Why Luis and his co-founder, two machine learning engineers, decided to start a bio-startup. How Immunai uses single-cell genomics to map the immune system. The trajectory of Immunai’s experiments from the laboratory to the patient.
@Azeem
@exponentialview
@Immunaitech
Further sources:
Scaling Synthetic Biology (with Gingko’s Reshma Shetty), Exponential View Podcast, 2022
The Future of Healthcare: Personalization and AI (with ZOE’s Jonathan Wolf), Exponential View Podcast, 2022
A transcript of this episode will be available by April 13, 2022.
This post Unlocking the Immune System (with Luis Voloch from Immunai)
was original published at “https://hbr.org/podcast/2022/04/ai-and-cancer-unlocking-the-immune-system-with-immunais-luis-voloch”
